Letrozole (Femara)

==General information==
Class/mechanism: Selective non-steroidal aromatase inhibitor. The aromatase enzyme converts adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues. Letrozole competitively binds to and inhibits the aromatase by binding to the heme of the enzyme's cytochrome P450.Letrozole (Femara) package insert Letrozole (Femara) package insert (locally hosted backup)Femara manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*ER/PR+ Breast cancer
*Low-grade serous ovarian cancer
==Patient drug information==
*Letrozole (Femara) package insert
*Letrozole (Femara) patient drug information (Chemocare)Letrozole (Femara) patient drug information (Chemocare)
*Letrozole (Femara) patient drug information (UpToDate)Letrozole (Femara) patient drug information (UpToDate)
==History of changes in FDA indication==
*1997-07-25: Initial approval for the treatment of advanced breast cancer in postmenopausal women
*2004-10-29: Accelerated approval for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. (Indication expanded to adjuvant setting after prior therapy; based on NCIC-CTG MA.17)
**2010-04-30: Converted to regular approval.
*2005-12-28: Accelerated approval for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. (Indication expanded to adjuvant setting; based on BIG 1-98)
**2010-04-30: Converted to regular approval.
*2010-03-02: Label simplified to adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. (No change)
*2010-03-02: Label simplified to extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. (Years requirement removed)
*2010-03-02: Label simplified to first and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. (Based on ILBCG, AR/BC2, AR/BC3)
==History of changes in EMA indication==
The approval of this drug pre-dates the EMA.
*1996-07-24: EURD
==History of changes in Health Canada indication==
*2005-04-01: Initial notice of compliance with conditions
*2010-12-17: Conditions were met
==History of changes in PMDA indication==
*2006-01-23: Initial approval for the treatment of post-menopausal breast cancer.
==Also known as==
*Code name: CGS-20267
*Brand names: Femara, Fempro, Gynotril, Latrotal, Lerozol, Letoval, Letpro, Letromina, Letroplex, Letroz, Letrozol, Lexel, Lezole
==References==
Category:Drugs
Category:Oral medications
Category:Protein expression-specific medications
Category:Aromatase inhibitors, third generation
Category:Breast cancer medications
Category:Low-grade serous ovarian cancer medications
Category:EMA approved in 1996
Category:FDA approved in 1997
Category:Health Canada approved in 2005
Category:PMDA approved in 2006